Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.146,71
-0,54%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Allarity Therapeutics Inc (ALLR) Allarity Therapeutics Inc (ALLR) Notizie

ALLR

Allarity Therapeutics (ALLR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLR
DataOraFonteTitoloSimboloCompagnia
19/11/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
18/11/202414:00GlobeNewswire Inc.Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsNASDAQ:ALLRAllarity Therapeutics Inc
14/11/202422:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
14/11/202414:00GlobeNewswire Inc.Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsNASDAQ:ALLRAllarity Therapeutics Inc
22/10/202414:00GlobeNewswire Inc.Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for StenoparibNASDAQ:ALLRAllarity Therapeutics Inc
10/10/202414:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
03/10/202414:00GlobeNewswire Inc.Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor ProgramNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
16/09/202414:00GlobeNewswire Inc.Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer TrialNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202414:45GlobeNewswire Inc.Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALLRAllarity Therapeutics Inc
11/09/202414:00GlobeNewswire Inc.Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)NASDAQ:ALLRAllarity Therapeutics Inc
10/09/202415:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
09/09/202422:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
30/08/202422:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
29/08/202423:57Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202415:00GlobeNewswire Inc.Allarity Therapeutics Announces Postponement of Annual Stockholders MeetingNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202412:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALLRAllarity Therapeutics Inc
24/07/202412:00GlobeNewswire Inc.Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesNASDAQ:ALLRAllarity Therapeutics Inc
22/07/202412:30GlobeNewswire Inc.Allarity Therapeutics Outlines Company’s 2024 Progress and ObjectivesNASDAQ:ALLRAllarity Therapeutics Inc
27/06/202414:00GlobeNewswire Inc.Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining ComplianceNASDAQ:ALLRAllarity Therapeutics Inc
25/06/202414:00GlobeNewswire Inc.Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
20/05/202414:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementNASDAQ:ALLRAllarity Therapeutics Inc
14/05/202422:01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
08/05/202422:05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
07/05/202415:30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202414:00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
02/05/202414:00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
17/04/202415:10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
04/04/202415:15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLR

La tua Cronologia

LSE
11MC
Investec Bnk 23
NASDAQ
AGMH
AGM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network